The Commercial-Grade Lipid Kit is built on clinically validated cationic lipids. SM-102, a key component of Moderna’s COVID-19 mRNA vaccine, has demonstrated excellent in vivo delivery efficiency and safety in hundreds of millions of doses worldwide.

Using a standardized manufacturing process, the kit enables efficient encapsulation of mRNA, siRNA, and other nucleic acids, with uniform particle size and reliable delivery performance. The simplified formulation process reduces experimental variability and is ideal for nucleic acid drug screening, vaccine development, and gene therapy research—providing a high-efficiency, reproducible in vivo delivery solution.